Clinical trial
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
NCT00005967 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005967 |
|---|---|
| Title | Tipifarnib in Treating Patients With Advanced Hematologic Cancer |
| Official title | A Dose Finding Study of R115777 (NSC 702818) in Patients With Advanced Hematologic Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | tipifarnib |
| Enrollment | 36 |
| Start date | Aug 1, 2000 |
| Primary completion | Apr 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: